Cargando…
Anlotinib Inhibits PFKFB3-Driven Glycolysis in Myofibroblasts to Reverse Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) is a fatal disease in which the normal alveolar network is gradually replaced by fibrotic scars. Current evidence suggests that metabolic alterations correlate with myofibroblast activation in IPF. Anlotinib has been proposed to have antifibrotic effects, but the...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8481786/ https://www.ncbi.nlm.nih.gov/pubmed/34603058 http://dx.doi.org/10.3389/fphar.2021.744826 |
_version_ | 1784576757018394624 |
---|---|
author | Chen, Weimou Zhang, Jinming Zhong, Wenshan Liu, Yuanyuan Lu, Ye Zeng, Zhaojin Huang, Haohua Wan, Xuan Meng, Xiaojing Zou, Fei Cai, Shaoxi Dong, Hangming |
author_facet | Chen, Weimou Zhang, Jinming Zhong, Wenshan Liu, Yuanyuan Lu, Ye Zeng, Zhaojin Huang, Haohua Wan, Xuan Meng, Xiaojing Zou, Fei Cai, Shaoxi Dong, Hangming |
author_sort | Chen, Weimou |
collection | PubMed |
description | Idiopathic pulmonary fibrosis (IPF) is a fatal disease in which the normal alveolar network is gradually replaced by fibrotic scars. Current evidence suggests that metabolic alterations correlate with myofibroblast activation in IPF. Anlotinib has been proposed to have antifibrotic effects, but the efficacy and mechanisms of anlotinib against lung fibrosis have not been systematically evaluated. The antifibrotic effects of anlotinib were evaluated in bleomycin-induced mouse models and transforming growth factor-beta 1 (TGF-β1)-stimulated lung fibroblasts. We measured lactate levels, 2-NBDG glucose uptake and the extracellular acidification rate (ECAR) to assess glycolysis in fibroblasts. RNA-protein coimmunoprecipitation (RIP) and polysome analyses were performed to investigate novel mechanisms of glycolytic reprogramming in pulmonary fibrosis. We found that anlotinib diminished myofibroblast activation and inhibited the augmentation of glycolysis. Moreover, we show that PCBP3 posttranscriptionally increases PFKFB3 expression by promoting its translation during myofibroblast activation, thus promoting glycolysis in myofibroblasts. Regarding mechanism, anlotinib exerts potent antifibrotic effects by downregulating PCBP3, reducing PFKFB3 translation and inhibiting glycolysis in myofibroblasts. Furthermore, we observed that anlotinib had preventative and therapeutic antifibrotic effects on bleomycin-induced pulmonary fibrosis. Therefore, we identify PCBP3 as a protein involved in the regulation of glycolysis reprogramming and lung fibrogenesis and propose it as a therapeutic target for pulmonary fibrosis. Our data suggest that anlotinib has antifibrotic effects on the lungs, and we provide a novel mechanism for this effect. Anlotinib may constitute a novel and potent candidate for the treatment of pulmonary fibrosis. |
format | Online Article Text |
id | pubmed-8481786 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84817862021-10-01 Anlotinib Inhibits PFKFB3-Driven Glycolysis in Myofibroblasts to Reverse Pulmonary Fibrosis Chen, Weimou Zhang, Jinming Zhong, Wenshan Liu, Yuanyuan Lu, Ye Zeng, Zhaojin Huang, Haohua Wan, Xuan Meng, Xiaojing Zou, Fei Cai, Shaoxi Dong, Hangming Front Pharmacol Pharmacology Idiopathic pulmonary fibrosis (IPF) is a fatal disease in which the normal alveolar network is gradually replaced by fibrotic scars. Current evidence suggests that metabolic alterations correlate with myofibroblast activation in IPF. Anlotinib has been proposed to have antifibrotic effects, but the efficacy and mechanisms of anlotinib against lung fibrosis have not been systematically evaluated. The antifibrotic effects of anlotinib were evaluated in bleomycin-induced mouse models and transforming growth factor-beta 1 (TGF-β1)-stimulated lung fibroblasts. We measured lactate levels, 2-NBDG glucose uptake and the extracellular acidification rate (ECAR) to assess glycolysis in fibroblasts. RNA-protein coimmunoprecipitation (RIP) and polysome analyses were performed to investigate novel mechanisms of glycolytic reprogramming in pulmonary fibrosis. We found that anlotinib diminished myofibroblast activation and inhibited the augmentation of glycolysis. Moreover, we show that PCBP3 posttranscriptionally increases PFKFB3 expression by promoting its translation during myofibroblast activation, thus promoting glycolysis in myofibroblasts. Regarding mechanism, anlotinib exerts potent antifibrotic effects by downregulating PCBP3, reducing PFKFB3 translation and inhibiting glycolysis in myofibroblasts. Furthermore, we observed that anlotinib had preventative and therapeutic antifibrotic effects on bleomycin-induced pulmonary fibrosis. Therefore, we identify PCBP3 as a protein involved in the regulation of glycolysis reprogramming and lung fibrogenesis and propose it as a therapeutic target for pulmonary fibrosis. Our data suggest that anlotinib has antifibrotic effects on the lungs, and we provide a novel mechanism for this effect. Anlotinib may constitute a novel and potent candidate for the treatment of pulmonary fibrosis. Frontiers Media S.A. 2021-09-16 /pmc/articles/PMC8481786/ /pubmed/34603058 http://dx.doi.org/10.3389/fphar.2021.744826 Text en Copyright © 2021 Chen, Zhang, Zhong, Liu, Lu, Zeng, Huang, Wan, Meng, Zou, Cai and Dong. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Chen, Weimou Zhang, Jinming Zhong, Wenshan Liu, Yuanyuan Lu, Ye Zeng, Zhaojin Huang, Haohua Wan, Xuan Meng, Xiaojing Zou, Fei Cai, Shaoxi Dong, Hangming Anlotinib Inhibits PFKFB3-Driven Glycolysis in Myofibroblasts to Reverse Pulmonary Fibrosis |
title | Anlotinib Inhibits PFKFB3-Driven Glycolysis in Myofibroblasts to Reverse Pulmonary Fibrosis |
title_full | Anlotinib Inhibits PFKFB3-Driven Glycolysis in Myofibroblasts to Reverse Pulmonary Fibrosis |
title_fullStr | Anlotinib Inhibits PFKFB3-Driven Glycolysis in Myofibroblasts to Reverse Pulmonary Fibrosis |
title_full_unstemmed | Anlotinib Inhibits PFKFB3-Driven Glycolysis in Myofibroblasts to Reverse Pulmonary Fibrosis |
title_short | Anlotinib Inhibits PFKFB3-Driven Glycolysis in Myofibroblasts to Reverse Pulmonary Fibrosis |
title_sort | anlotinib inhibits pfkfb3-driven glycolysis in myofibroblasts to reverse pulmonary fibrosis |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8481786/ https://www.ncbi.nlm.nih.gov/pubmed/34603058 http://dx.doi.org/10.3389/fphar.2021.744826 |
work_keys_str_mv | AT chenweimou anlotinibinhibitspfkfb3drivenglycolysisinmyofibroblaststoreversepulmonaryfibrosis AT zhangjinming anlotinibinhibitspfkfb3drivenglycolysisinmyofibroblaststoreversepulmonaryfibrosis AT zhongwenshan anlotinibinhibitspfkfb3drivenglycolysisinmyofibroblaststoreversepulmonaryfibrosis AT liuyuanyuan anlotinibinhibitspfkfb3drivenglycolysisinmyofibroblaststoreversepulmonaryfibrosis AT luye anlotinibinhibitspfkfb3drivenglycolysisinmyofibroblaststoreversepulmonaryfibrosis AT zengzhaojin anlotinibinhibitspfkfb3drivenglycolysisinmyofibroblaststoreversepulmonaryfibrosis AT huanghaohua anlotinibinhibitspfkfb3drivenglycolysisinmyofibroblaststoreversepulmonaryfibrosis AT wanxuan anlotinibinhibitspfkfb3drivenglycolysisinmyofibroblaststoreversepulmonaryfibrosis AT mengxiaojing anlotinibinhibitspfkfb3drivenglycolysisinmyofibroblaststoreversepulmonaryfibrosis AT zoufei anlotinibinhibitspfkfb3drivenglycolysisinmyofibroblaststoreversepulmonaryfibrosis AT caishaoxi anlotinibinhibitspfkfb3drivenglycolysisinmyofibroblaststoreversepulmonaryfibrosis AT donghangming anlotinibinhibitspfkfb3drivenglycolysisinmyofibroblaststoreversepulmonaryfibrosis |